Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Affluent Partners Holdings ( (HK:1466) ) has provided an update.
Baijin Life Science Holdings Limited, through its subsidiary Beijing Baijin Biotechnology, has entered into a strategic cooperation framework agreement with Youhuan Biopharmaceutical Technology. This collaboration aims to establish a leading circular RNA technology R&D platform to innovate in cell therapy, focusing on circRNA-based therapies for liver diseases, drug delivery technologies, and cell reprogramming for genetic diseases. The agreement is part of Baijin’s strategy to diversify its business and broaden its income streams, although it is still in the preliminary stages and subject to further agreements.
The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.
More about Affluent Partners Holdings
Average Trading Volume: 462,491
Technical Sentiment Signal: Hold
Current Market Cap: HK$526.4M
See more data about 1466 stock on TipRanks’ Stock Analysis page.